CHD Stock Forecast & Price Target

Church & Dwight Co is favored because its growth is being driven by volume rather than price, with organic sales up 5% on 5.3% volume growth and distribution gains running about 10%–11%, roughly 2x peers. Its portfolio is resilient and innovation-led, as Arm & Hammer, Batiste, OxiClean, Hero, Therabreath, and Touchland support around 70% of sales and profits, while low U.S. penetration and strong brand extensions leave room for further share gains. Financial discipline also supports the outlook: leverage is only 1.5x, productivity is offsetting cost pressures, and management’s acquisition track record, including Miss Mouth’s Messy Eater, adds another lever for growth.

Church & Dwight Co is viewed negatively because its earnings quality is pressured by persistent cost and demand risks, including an incremental $25–$30 million of cost inflation this year from oil and oil-based derivatives, with only about 60% hedged. The company also expects 2Q EPS to come down versus prior consensus and only about flat EPS growth in H1, while international organic sales expectations for the year were trimmed to about 7% from 7–8% due to the Middle East conflict. Its heavy reliance on the U.S., Walmart’s more than 20% sales share, and the execution risk of integrating Touchland after fiscal 2025 add further downside if promotions, input costs, or product launches disappoint.